These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1748 related articles for article (PubMed ID: 19877380)
1. Prasugrel: new drug. After angioplasty and stenting: continue to use aspirin + clopidogrel. Prescrire Int; 2009 Oct; 18(103):193-5. PubMed ID: 19877380 [TBL] [Abstract][Full Text] [Related]
2. Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thrombolysis In Myocardial Infarction) analysis. Antman EM; Wiviott SD; Murphy SA; Voitk J; Hasin Y; Widimsky P; Chandna H; Macias W; McCabe CH; Braunwald E J Am Coll Cardiol; 2008 May; 51(21):2028-33. PubMed ID: 18498956 [TBL] [Abstract][Full Text] [Related]
3. The potential role of prasugrel in secondary prevention of ischemic events in patients with acute coronary syndromes. Toth PP Postgrad Med; 2009 Jan; 121(1):59-72. PubMed ID: 19179814 [TBL] [Abstract][Full Text] [Related]
4. The efficacy and safety of prasugrel with and without a glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes undergoing percutaneous intervention: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38) analysis. O'Donoghue M; Antman EM; Braunwald E; Murphy SA; Steg PG; Finkelstein A; Penny WF; Fridrich V; McCabe CH; Sabatine MS; Wiviott SD J Am Coll Cardiol; 2009 Aug; 54(8):678-85. PubMed ID: 19679245 [TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of prasugrel compared with clopidogrel in patients with acute coronary syndromes: results of TRITON-TIMI 38 trials. Mariani M; Mariani G; De Servi S Expert Rev Cardiovasc Ther; 2009 Jan; 7(1):17-23. PubMed ID: 19105763 [TBL] [Abstract][Full Text] [Related]
6. Role of prasugrel, a novel P2Y(12) receptor antagonist, in the management of acute coronary syndromes. Baker WL; White CM Am J Cardiovasc Drugs; 2009; 9(4):213-29. PubMed ID: 19655817 [TBL] [Abstract][Full Text] [Related]
7. Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38). Wiviott SD; Antman EM; Gibson CM; Montalescot G; Riesmeyer J; Weerakkody G; Winters KJ; Warmke JW; McCabe CH; Braunwald E; Am Heart J; 2006 Oct; 152(4):627-35. PubMed ID: 16996826 [TBL] [Abstract][Full Text] [Related]
8. Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 trial. Wiviott SD; Antman EM; Winters KJ; Weerakkody G; Murphy SA; Behounek BD; Carney RJ; Lazzam C; McKay RG; McCabe CH; Braunwald E; Circulation; 2005 Jun; 111(25):3366-73. PubMed ID: 15967851 [TBL] [Abstract][Full Text] [Related]
9. Effect of prasugrel versus clopidogrel on outcomes among patients with acute coronary syndrome undergoing percutaneous coronary intervention without stent implantation: a TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet inhibitioN with prasugrel (TRITON)-Thrombolysis in Myocardial Infarction (TIMI) 38 substudy. Pride YB; Wiviott SD; Buros JL; Zorkun C; Tariq MU; Antman EM; Braunwald E; Gibson CM; Am Heart J; 2009 Sep; 158(3):e21-6. PubMed ID: 19699846 [TBL] [Abstract][Full Text] [Related]
10. Indications for dual antiplatelet therapy with aspirin and clopidogrel: evidence-based recommendations for use. Reaume KT; Regal RE; Dorsch MP Ann Pharmacother; 2008 Apr; 42(4):550-7. PubMed ID: 18319394 [TBL] [Abstract][Full Text] [Related]
11. Study design and rationale of a comparison of prasugrel and clopidogrel in medically managed patients with unstable angina/non-ST-segment elevation myocardial infarction: the TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY manage Acute Coronary Syndromes (TRILOGY ACS) trial. Chin CT; Roe MT; Fox KA; Prabhakaran D; Marshall DA; Petitjean H; Lokhnygina Y; Brown E; Armstrong PW; White HD; Ohman EM; Am Heart J; 2010 Jul; 160(1):16-22.e1. PubMed ID: 20598967 [TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of prasugrel versus clopidogrel in patients with acute coronary syndromes and planned percutaneous coronary intervention: results from the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with Prasugrel-Thrombolysis in Myocardial Infarction TRITON-TIMI 38. Mahoney EM; Wang K; Arnold SV; Proskorovsky I; Wiviott S; Antman E; Braunwald E; Cohen DJ Circulation; 2010 Jan; 121(1):71-9. PubMed ID: 20026770 [TBL] [Abstract][Full Text] [Related]
13. Effect of the novel thienopyridine prasugrel compared with clopidogrel on spontaneous and procedural myocardial infarction in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardial Infarction 38: an application of the classification system from the universal definition of myocardial infarction. Morrow DA; Wiviott SD; White HD; Nicolau JC; Bramucci E; Murphy SA; Bonaca MP; Ruff CT; Scirica BM; McCabe CH; Antman EM; Braunwald E Circulation; 2009 Jun; 119(21):2758-64. PubMed ID: 19451347 [TBL] [Abstract][Full Text] [Related]
14. Prasugrel: Clinical development and therapeutic application. Guerra DR; Tcheng JE Adv Ther; 2009 Nov; 26(11):999-1011. PubMed ID: 20020231 [TBL] [Abstract][Full Text] [Related]
15. Prasugrel development - claims and achievements. Serebruany V; Shalito I; Kopyleva O Thromb Haemost; 2009 Jan; 101(1):14-22. PubMed ID: 19132184 [TBL] [Abstract][Full Text] [Related]